Efficacy and Safety of SBRT Followed by Tislelizumab Plus Cetuximab and Irinotecan in Patients With Previously Treated RAS Wild-type Advanced Refractory Colorectal Cancer
To evaluate the efficacy and safety of SBRT followed by tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced refractory colorectal cancer
Colorectal Cancer
DRUG: Tislelizumab|DRUG: Irinotecan Hydrochloride|DRUG: cetuximab|RADIATION: SBRT
Objective response rate(ORR), ORR was defined as percentage of participants with best (confirmed) overall response (BOR) of either CR or PR, From enrollment to 12 month
Progression-Free Survival(PFS), PFS was defined as the time from randomization to first documented disease progression (PD) using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1) or death from any cause, whichever occurred first, From enrollment to 12 month|Overall Survival (OS), Overall Survival (OS), defined as the time from the date of randomization to the date of death, regardless of the cause of death., From enrollment to 12 month
To evaluate the efficacy and safety of SBRT followed by tislelizumab plus cetuximab and irinotecan in patients with previously treated RAS wild-type advanced refractory colorectal cancer